Company / Cash & Equivalents
Krystal Biotech, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$496.3M
FY2025
5-year range
$161.9M / $496.3M
FY2021-FY2025
Trend
+43.9%
vs FY2024
Sector context
#41 of 207
Health Care
What the data says
Krystal Biotech, Inc.'s cash & equivalents of $496M is higher than 80% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $2M in FY2016 to $496M in FY2025.
Based on SEC 10-K filings.
$496M in FY2025 with a 5-year CAGR of +13.1%. Top quartile in the Health Care sector.
Improved from $358M to $496M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +45.3%
- 5-Year CAGR
- +13.1%
- 10-Year CAGR
- -
Sector benchmark
-25.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +13.1%, indicating consistent growth.
- In FY2025, cash & equivalents increased 43.9% year-over-year.
- Ranks #41 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 5.66 (safe zone, above 2.9 threshold)
- Strong profit margin: 30.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $496.3M | +43.9% |
| FY2024 | $344.9M | -3.8% |
| FY2023 | $358.3M | +121.3% |
| FY2022 | $161.9M | -52.6% |
| FY2021 | $341.2M | +27.2% |
| FY2020 | $268.3M | +43.1% |
| FY2019 | $187.5M | +80.9% |
| FY2018 | $103.7M | +109.1% |
| FY2017 | $49.6M | +2478.8% |
| FY2016 | $1.9M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026